Future applications of FGF/FGFR inhibitors in cancer

References

• Ornitz DM, Itoh N. The fibroblast growth factor signaling pathway. Wiley Interdiscip Rev Dev Biol. 2015;4:215–266.
   PubMed Web of Science ®Google Scholar
• Holzmann K, Grunt T, Heinzle C, et al. Alternative splicing of fibroblast growth factor receptor IgIII loops in cancer. J Nucleic Acids. 2012;2012:1–12.
   Google Scholar
• Eswarakumar VP, Lax I, Schlessinger J. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005;16:139–149.
   PubMed Web of Science ®Google Scholar
• Ishiwata T. Role of fibroblast growth factor receptor-2 splicing in normal and cancer cells. Front Biosci (Landmark Ed). 2018;23:626–639.
   PubMed Web of Science ®Google Scholar
• Trueb B. Biology of FGFRL1, the fifth fibroblast growth factor receptor. Cell Mol Life Sci. 2011;68:951–964.
   PubMed Web of Science ®Google Scholar
• Silva PN, Altamentova SM, Kilkenny DM, et al. Fibroblast growth factor receptor like-1 (FGFRL1) interacts with SHP-1 phosphatase at insulin secretory granules and induces beta-cell ERK1/2 protein activation. J Biol Chem. 2013;288:17859–17870.
   PubMed Web of Science ®Google Scholar
• Itoh N, Ornitz DM. Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem. 2011;149:121–130.
   PubMed Web of Science ®Google Scholar
• Richard C, Liuzzo JP, Moscatelli D. Fibroblast growth factor-2 can mediate cell attachment by linking receptors and heparan sulfate proteoglycans on neighboring cells. J Biol Chem. 1995;270:24188–24196.
   PubMed Web of Science ®Google Scholar
• Wan X, Corn PG, Yang J, et al. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Sci Transl Med. 2014;6:252ra122.
   PubMed Web of Science ®Google Scholar
• Giacomini A, Chiodelli P, Matarazzo S, et al. Blocking the FGF/FGFR system as a “two-compartment” antiangiogenic/antitumor approach in cancer therapy. Pharmacol Res. 2016;107:172–185.
   PubMed Web of Science ®Google Scholar
• Helsten T, Elkin S, Arthur E, et al. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22:259–267.
   PubMed Web of Science ®Google Scholar
• Helsten T, Schwaederle M, Kurzrock R. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications. Cancer Metastasis Rev. 2015;34:479–496.
   PubMed Web of Science ®Google Scholar
• Babina IS, Turner NC. Advances and challenges in targeting FGFR signalling in cancer. Nat Rev Cancer. 2017;17:318–332.
   PubMed Web of Science ®Google Scholar
• Weiss J, Sos ML, Seidel D, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med. 2010;2:62ra93.
   PubMed Web of Science ®Google Scholar
• Peifer M, Fernández-Cuesta L, Sos ML, et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet. 2012;44:1104–1110.
   PubMed Web of Science ®Google Scholar
• Turner N, Pearson A, Sharpe R, et al. FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res. 2010;70:2085–2094.
   PubMed Web of Science ®Google Scholar
• Fischbach A, Rogler A, Erber R, et al. Fibroblast growth factor receptor (FGFR) gene amplifications are rare events in bladder cancer. Histopathology. 2015;66:639–649.
   PubMed Web of Science ®Google Scholar
• Hart KC, Robertson SC, Kanemitsu MY, et al. Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4. Oncogene. 2000;19:3309–3320.
   PubMed Web of Science ®Google Scholar
• Lew ED, Furdui CM, Anderson KS, et al. The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations. Sci Signal. 2009;2:ra6.
   PubMed Web of Science ®Google Scholar
• Agelopoulos K, Richter GH, Schmidt E, et al. Deep sequencing in conjunction with expression and functional analyses reveals activation of FGFR1 in Ewing Sarcoma. Clin Cancer Res. 2015;21:4935–4946.
   PubMed Web of Science ®Google Scholar
• Gallo LH, Nelson KN, Meyer AN, et al. Functions of fibroblast growth factor receptors in cancer defined by novel translocations and mutations. Cytokine Growth Factor Rev. 2015;26:425–449.
   PubMed Web of Science ®Google Scholar
• Schram AM, Chang MT, Jonsson P, et al. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat Rev Clin Oncol. 2017;14:735–748.
   PubMed Web of Science ®Google Scholar
• Landberg N, Dreimane A, Rissler M, et al. Primary cells in BCR/FGFR1-positive 8p11 myeloproliferative syndrome are sensitive to dovitinib, ponatinib, and dasatinib. Eur J Haematol. 2017;99:442–448.
   PubMed Web of Science ®Google Scholar
• André F, Cortés J. Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res Treat. 2015;150:1–8.
   PubMed Web of Science ®Google Scholar
• Burstein MD, Tsimelzon A, Poage GM, et al. Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer. Clin Cancer Res. 2015;21:1688–1698.
   PubMed Web of Science ®Google Scholar
• Su X, Zhan P, Gavine PR, et al. FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study. Br J Cancer. 2014;110:967–975.
   PubMed Web of Science ®Google Scholar
• Ahn S, Lee J, Hong M, et al. FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival. Mod Pathol. 2016;29:1095–1103.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research N. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–209.
   PubMed Web of Science ®Google Scholar
• Dutt A, Salvesen HB, Chen T-H, et al. Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci U S A. 2008;105:8713–8717.
   PubMed Web of Science ®Google Scholar
• Tchaicha JH, Akbay EA, Altabef A, et al. Kinase domain activation of FGFR2 yields high-grade lung adenocarcinoma sensitive to a Pan-FGFR inhibitor in a mouse model of NSCLC. Cancer Res. 2014;74:4676–4684.
   PubMedGoogle Scholar
• Tanizaki J, Ercan D, Capelletti M, et al. Identification of oncogenic and drug-sensitizing mutations in the extracellular domain of FGFR2. Cancer Res. 2015;75:3139–3146.
   PubMed Web of Science ®Google Scholar
• Jung E-J, Jung E-J, Min SY, et al. Fibroblast growth factor receptor 2 gene amplification status and its clinicopathologic significance in gastric carcinoma. Hum Pathol. 2012;43:1559–1566.
   PubMed Web of Science ®Google Scholar
• Baldia PH, Maurer A, Heide T, et al. Fibroblast growth factor receptor (FGFR) alterations in squamous differentiated bladder cancer: a putative therapeutic target for a small subgroup. Oncotarget. 2016;7(44):71429–71439.
   PubMedGoogle Scholar
• Wu Y-M, Su F, Kalyana-Sundaram S, et al. Identification of targetable FGFR gene fusions in diverse cancers. Cancer Discov. 2013;3:636–647.
   PubMed Web of Science ®Google Scholar
• Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59:1427–1434.
   PubMed Web of Science ®Google Scholar
• Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun. 2015;6:6087.
   PubMed Web of Science ®Google Scholar
• Vékony H, Ylstra B, Wilting SM, et al. DNA copy number gains at loci of growth factors and their receptors in salivary gland adenoid cystic carcinoma. Clin Cancer Res. 2007;13:3133–3139.
   PubMed Web of Science ®Google Scholar
• Bernard-Pierrot I, Brams A, Dunois-Lardé C, et al. Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b. Carcinogenesis. 2006;27:740–747.
   PubMed Web of Science ®Google Scholar
• Liu X, Zhang W, Geng D, et al. Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis. Genet Mol Res. 2014;13:1109–1120.
   PubMed Web of Science ®Google Scholar
• Solomon JP, Hansel DE. The emerging molecular landscape of urothelial carcinoma. Surg Pathol Clin. 2016;9:391–394.
   PubMedGoogle Scholar
• Dodurga Y, Tataroglu C, Kesen Z, et al. Incidence of fibroblast growth factor receptor 3 gene (FGFR3) A248C, S249C, G372C, and T375C mutations in bladder cancer. Genet Mol Res. 2011;10:86–95.
   PubMed Web of Science ®Google Scholar
• Rosty C, Aubriot M-H, Cappellen D, et al. Clinical and biological characteristics of cervical neoplasias with FGFR3 mutation. Mol Cancer. 2005;4:15.
   PubMed Web of Science ®Google Scholar
• Chesi M, Nardini E, Brents LA, et al. Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3. Nat Genet. 1997;16:260–264.
   PubMed Web of Science ®Google Scholar
• Soverini S, Terragna C, Testoni N, et al. Novel mutation and RNA splice variant of fibroblast growth factor receptor 3 in multiple myeloma patients at diagnosis. Haematologica. 2002;87:1036–1040.
   PubMed Web of Science ®Google Scholar
• Goriely A, Hansen RM, Taylor IB, et al. Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors. Nat Genet. 2009;41:1247–1252.
   PubMed Web of Science ®Google Scholar
• Feldman DR, Iyer G, Van Alstine L, et al. Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors. Clin Cancer Res. 2014;20:3712–3720.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hiraishi Y, Wang H, et al. Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas. Int J Cancer. 2005;117:166–168.
   PubMed Web of Science ®Google Scholar
• Singh D, Chan JM, Zoppoli P, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012;337:1231–1235.
   PubMed Web of Science ®Google Scholar
• Williams SV, Hurst CD, Knowles MA. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet. 2013;22:795–803.
   PubMed Web of Science ®Google Scholar
• Shaver TM, Lehmann BD, Beeler JS, et al. Diverse, biologically relevant, and targetable gene rearrangements in triple-negative breast cancer and other malignancies. Cancer Res. 2016;76:4850–4860.
   PubMed Web of Science ®Google Scholar
• Daly C, Castanaro C, Zhang W, et al. FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling. Oncogene. 2017;36:471–481.
   PubMed Web of Science ®Google Scholar
• Kalff A, Spencer A. The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies. Blood Cancer J. 2012;2:e89.
   PubMed Web of Science ®Google Scholar
• Chesi M, Brents LA, Ely SA, et al. Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma. Blood. 2001;97:729–736.
   PubMed Web of Science ®Google Scholar
• Sun X, Guo W, Shen JK, et al. Rhabdomyosarcoma: advances in molecular and cellular biology. Sarcoma. 2015;2015:232010.
   PubMedGoogle Scholar
• Seki M, Nishimura R, Yoshida K, et al. Integrated genetic and epigenetic analysis defines novel molecular subgroups in rhabdomyosarcoma. Nat Commun. 2015;6:7557.
   PubMed Web of Science ®Google Scholar
• Tanner Y, Grose RP. Dysregulated FGF signalling in neoplastic disorders. Semin Cell Dev Biol. 2016;53:126–135.
   PubMed Web of Science ®Google Scholar
• Ronca R, Giacomini A, Rusnati M, et al. The potential of fibroblast growth factor/fibroblast growth factor receptor signaling as a therapeutic target in tumor angiogenesis. Expert Opin Ther Targets. 2015;19:1361–1377.
   PubMed Web of Science ®Google Scholar
• Jing Q, Wang Y, Liu H, et al. FGFs: crucial factors that regulate tumour initiation and progression. Cell Prolif. 2016;49:438–447.
   PubMed Web of Science ®Google Scholar
• Ghassemi S, Vejdovszky K, Sahin E, et al. FGF5 is expressed in melanoma and enhances malignancy in vitro and in vivo. Oncotarget. 2017;8:87750–87762.
   PubMedGoogle Scholar
• Ronca R, Di Salle E, Giacomini A, et al. Long pentraxin-3 inhibits epithelial-mesenchymal transition in melanoma cells. Mol Cancer Ther. 2013;12:2760–2771.
   PubMed Web of Science ®Google Scholar
• Giacomini A, Matarazzo S, Pagano K, et al. A long pentraxin-3-derived pentapeptide for the therapy of FGF8b-driven steroid hormone-regulated cancers. Oncotarget. 2015;6:13790–13792.
   PubMedGoogle Scholar
• Tuomela J, Härkönen P. Tumor models for prostate cancer exemplified by fibroblast growth factor 8-induced tumorigenesis and tumor progression. Reprod Biol. 2014;14:16–24.
   PubMed Web of Science ®Google Scholar
• Nagamatsu H, Teishima J, Goto K, et al. FGF19 promotes progression of prostate cancer. Prostate. 2015;75:1092–1101.
   PubMedGoogle Scholar
• Feng S, Wang J, Zhang Y, et al. FGF23 promotes prostate cancer progression. Oncotarget. 2015;6:17291–17301.
   PubMedGoogle Scholar
• Lee EK, Martinez MC, Blakely K, et al. FGF23: mediator of poor prognosis in a sizeable subgroup of patients with castration-resistant prostate cancer presenting with severe hypophosphatemia? Med Hypotheses. 2014;83:482–487.
   PubMed Web of Science ®Google Scholar
• Ronca R, Tamma R, Coltrini D, et al. Fibroblast growth factor modulates mast cell recruitment in a murine model of prostate cancer. Oncotarget. 2017;8:82583–82592.
   PubMedGoogle Scholar
• Bluemn EG, Coleman IM, Lucas JM, et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell. 2017;32:474–489, e476.
   PubMed Web of Science ®Google Scholar
• Sharpe R, Pearson A, Herrera-Abreu MT, et al. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res. 2011;17:5275–5286.
   PubMed Web of Science ®Google Scholar
• Aukes K, Forsman C, Brady NJ, et al. Breast cancer cell-derived fibroblast growth factors enhance osteoclast activity and contribute to the formation of metastatic lesions. PLoS One. 2017;12:e0185736.
   PubMed Web of Science ®Google Scholar
• Marek L, Ware KE, Fritzsche A, et al. Fibroblast growth factor (FGF) and FGF receptor-mediated autocrine signaling in non-small-cell lung cancer cells. Mol Pharmacol. 2009;75:196–197.
   PubMed Web of Science ®Google Scholar
• Qi L, Song W, Li L, et al. FGF4 induces epithelial-mesenchymal transition by inducing store-operated calcium entry in lung adenocarcinoma. Oncotarget. 2016;7:74015–74030.
   PubMedGoogle Scholar
• Birrer MJ, Johnson ME, Hao K, et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J Clin Oncol. 2007;25:2281–2287.
   PubMed Web of Science ®Google Scholar
• Sun Y, Fan X, Zhang Q, et al. Cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1/FGFR4 signaling. Tumour Biol. 2017;39:1010428317712592.
   Google Scholar
• Marshall ME, Hinz TK, Kono SA, et al. Fibroblast growth factor receptors are components of autocrine signaling networks in head and neck squamous cell carcinoma cells. Clin Cancer Res. 2011;17:5016–5025.
   PubMed Web of Science ®Google Scholar
• Maehara O, Suda G, Natsuizaka M, et al. Fibroblast growth factor-2-mediated FGFR/Erk signaling supports maintenance of cancer stem-like cells in esophageal squamous cell carcinoma. Carcinogenesis. 2017;38:1073–1083.
   PubMed Web of Science ®Google Scholar
• Soria J-C, DeBraud F, Bahleda R, et al. Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors. Ann Oncol. 2014;25:2244–2251.
   PubMed Web of Science ®Google Scholar
• Guffanti F, Chilà R, Bello E, et al. In vitro and in vivo activity of lucitanib in FGFR1/2 amplified or mutated cancer models. Neoplasia. 2017;19:35–42.
   PubMed Web of Science ®Google Scholar
• Formisano L, Stauffer KM, Young CD, et al. Association of FGFR1 with ERalpha maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER(+) breast cancer. Clin Cancer Res. 2017;23:6138–6150.
   PubMed Web of Science ®Google Scholar
• Sohl CD, Ryan MR, Luo B, et al. Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles’ heel of targeted therapy. ACS Chem Biol. 2015;10:1319–1329.
   PubMed Web of Science ®Google Scholar
• Awasthi N, Schwarz RE. Profile of nintedanib in the treatment of solid tumors: the evidence to date. Onco Targets Ther. 2015;8:3691–3701.
   PubMed Web of Science ®Google Scholar
• Reck M. Nintedanib: examining the development and mechanism of action of a novel triple angiokinase inhibitor. Expert Rev Anticancer Ther. 2015;15:579–594.
   PubMed Web of Science ®Google Scholar
• Hibi M, Kaneda H, Tanizaki J, et al. FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. Cancer Sci. 2016;107:1667–1676.
   PubMed Web of Science ®Google Scholar
• Porta C, Giglione P, Liguigli W, et al. Dovitinib (CHIR258, TKI258): structure, development and preclinical and clinical activity. Future Oncol. 2015;11:39–50.
   PubMed Web of Science ®Google Scholar
• Konecny GE, Kolarova T, O’Brien NA, et al. Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells. Mol Cancer Ther. 2013;12:632–642.
   PubMed Web of Science ®Google Scholar
• Kim HR, Kang HN, Shim HS, et al. Co-clinical trials demonstrate predictive biomarkers for dovitinib, an FGFR inhibitor, in lung squamous cell carcinoma. Ann Oncol. 2017;28:1250–1259.
   PubMed Web of Science ®Google Scholar
• André F, Bachelot T, Campone M, et al. Targeting FGFR with dovitinib (TKI258): preclinical and clinical data in breast cancer. Clin Cancer Res. 2013;19:3693–3702.
   PubMed Web of Science ®Google Scholar
• Musolino A, Campone M, Neven P, et al. Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR(+), HER2(-) breast cancer that had progressed during or after prior endocrine therapy. Breast Cancer Res. 2017;19:18.
   PubMed Web of Science ®Google Scholar
• Byron SA, Chen H, Wortmann A, et al. The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors. Neoplasia. 2013;15:975–988.
   PubMed Web of Science ®Google Scholar
• Patani H, Bunney TD, Thiyagarajan N, et al. Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use. Oncotarget. 2016;7:24252–24268.
   PubMedGoogle Scholar
• Trudel S, Li ZH, Wei E, et al. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood. 2005;105:2941–2948.
   PubMed Web of Science ®Google Scholar
• Scheid C, Reece D, Beksac M, et al. Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. Eur J Haematol. 2015;95:316–324.
   PubMed Web of Science ®Google Scholar
• Lee C-K, Lee ME, Lee WS, et al. Dovitinib (TKI258), a multi-target angiokinase inhibitor, is effective regardless of KRAS or BRAF mutation status in colorectal cancer. Am J Cancer Res. 2015;5:72–86.
   PubMed Web of Science ®Google Scholar
• Semrad TJ, Kim EJ, Tanaka MS, et al. Phase II study of dovitinib in patients progressing on anti-vascular endothelial growth factor therapy. Cancer Treat Res Commun. 2017;10:21–26.
   Google Scholar
• Angevin E, Lopez-Martin JA, Lin CC, et al. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Clin Cancer Res. 2013;19:1257–1268.
   PubMed Web of Science ®Google Scholar
• Motzer RJ, Hutson TE, Glen H, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16:1473–1482.
   PubMed Web of Science ®Google Scholar
• Yadav SS, Li J, Stockert JA, et al. Induction of neuroendocrine differentiation in prostate cancer cells by dovitinib (TKI-258) and its therapeutic implications. Transl Oncol. 2017;10:357–366.
   PubMed Web of Science ®Google Scholar
• Porta R, Borea R, Coelho A, et al. FGFR a promising druggable target in cancer: molecular biology and new drugs. Crit Rev Oncol Hematol. 2017;113:256–267.
   PubMed Web of Science ®Google Scholar
• Chae YK, Ranganath K, Hammerman PS, et al. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application. Oncotarget. 2017;8:16052–16074.
   PubMedGoogle Scholar
• Nogova L, Sequist LV, Perez Garcia JM, et al. Evaluation of BGJ398, a fibroblast growth factor receptor 1-3 kinase inhibitor, in patients with advanced solid tumors harboring genetic alterations in fibroblast growth factor receptors: results of a global phase I, dose-escalation and dose-expansion study. J Clin Oncol. 2017;35:157–165.
   PubMed Web of Science ®Google Scholar
• Tabernero J, Bahleda R, Dienstmann R, et al. Phase I dose-escalation study of JNJ-42756493, an oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2015;33:3401–3408.
   PubMed Web of Science ®Google Scholar
• Gavine PR, Mooney L, Kilgour E, et al. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 2012;72:2045–2056.
   PubMed Web of Science ®Google Scholar
• Jang J, Kim HK, Bang H, et al. Antitumor effect of AZD4547 in a fibroblast growth factor receptor 2-amplified gastric cancer patient-derived cell model. Transl Oncol. 2017;10:469–475.
   PubMed Web of Science ®Google Scholar
• Siegfried JM, Farooqui M, Rothenberger NJ, et al. Interaction between the estrogen receptor and fibroblast growth factor receptor pathways in non-small cell lung cancer. Oncotarget. 2017;8:24063–24076.
   PubMedGoogle Scholar
• Zhang J, Zhang L, Su X, et al. Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models. Clin Cancer Res. 2012;18:6658–6667.
   PubMed Web of Science ®Google Scholar
• Kwak Y, Cho H, Hur W, et al. Antitumor effects and mechanisms of AZD4547 on FGFR2-deregulated endometrial cancer cells. Mol Cancer Ther. 2015;14:2292–2302.
   PubMed Web of Science ®Google Scholar
• Yao T-J, Zhu J-H, Peng D-F, et al. AZD-4547 exerts potent cytostatic and cytotoxic activities against fibroblast growth factor receptor (FGFR)-expressing colorectal cancer cells. Tumour Biol. 2015;36:5641–5648.
   PubMedGoogle Scholar
• Zhao Q, Parris AB, Howard EW, et al. FGFR inhibitor, AZD4547, impedes the stemness of mammary epithelial cells in the premalignant tissues of MMTV-ErbB2 transgenic mice. Sci Rep. 2017;7:11306.
   PubMed Web of Science ®Google Scholar
• Zhang H-R, Wang X-D, Yang X, et al. An FGFR inhibitor converts the tumor promoting effect of TGF-beta by the induction of fibroblast-associated genes of hepatoma cells. Oncogene. 2017;36:3831–3841.
   PubMed Web of Science ®Google Scholar
• Packer LM, Geng X, Bonazzi VF, et al. PI3K inhibitors synergize with FGFR inhibitors to enhance antitumor responses in FGFR2(mutant) endometrial cancers. Mol Cancer Ther. 2017;16:637–648.
   PubMed Web of Science ®Google Scholar
• Lehnen NC, von Mässenhausen A, Kalthoff H, et al. Fibroblast growth factor receptor 1 gene amplification in pancreatic ductal adenocarcinoma. Histopathology. 2013;63:157–166.
   PubMed Web of Science ®Google Scholar
• Göke F, Göke A, von Mässenhausen A, et al. Fibroblast growth factor receptor 1 as a putative therapy target in colorectal cancer. Digestion. 2013;88:172–181.
   PubMed Web of Science ®Google Scholar
• Schmidt K, Moser C, Hellerbrand C, et al. Targeting fibroblast growth factor receptor (FGFR) with BGJ398 in a gastric cancer model. Anticancer Res. 2015;35:6655–6665.
   PubMed Web of Science ®Google Scholar
• Wang Y, Ding X, Wang S, et al. Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein. Cancer Lett. 2016;380:163–173.
   PubMed Web of Science ®Google Scholar
• Goyal L, Saha SK, Liu LY, et al. Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma. Cancer Discov. 2017;7:252–263.
   PubMed Web of Science ®Google Scholar
• Javle M, Lowery M, Shroff RT, et al. Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma. J Clin Oncol. 2018;36:276–282.
   PubMedGoogle Scholar
• Perera TPS, Jovcheva E, Mevellec L, et al. Discovery and pharmacological characterization of JNJ-42756493 (Erdafitinib), a functionally selective small-molecule FGFR family inhibitor. Mol Cancer Ther. 2017;16:1010–1020.
   PubMed Web of Science ®Google Scholar
• Di Stefano AL, Fucci A, Frattini V, et al. Detection, characterization, and inhibition of FGFR-TACC fusions in IDH wild-type glioma. Clin Cancer Res. 2015;21:3307–3317.
   PubMed Web of Science ®Google Scholar
• Katoh M. FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (review). Int J Mol Med. 2016;38:3–15.
   PubMed Web of Science ®Google Scholar
• Hierro C, Rodon J, Tabernero J. Fibroblast Growth Factor (FGF) receptor/FGF inhibitors: novel targets and strategies for optimization of response of solid tumors. Semin Oncol. 2015;42:801–819.
   PubMed Web of Science ®Google Scholar
• Dieci MV, Arnedos M, Andre F, et al. Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives. Cancer Discov. 2013;3:264–279.
   PubMed Web of Science ®Google Scholar
• Carter EP, Fearon AE, Grose RP. Careless talk costs lives: fibroblast growth factor receptor signalling and the consequences of pathway malfunction. Trends Cell Biol. 2015;25:221–233.
   PubMed Web of Science ®Google Scholar
• Lee J, Bang YJ, Rha SY, et al. Antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-selective monoclonal antibody, in patients with FGFR2b+ gastric cancer and advanced solid tumors. J Clin Oncol. 2016;24(15_suppl):2502.
   Google Scholar
• Catenacci DVT, Rha SY, Bang H, et al. Updated antitumor activity and safety of FPA144, an ADCC-enhanced, FGFR2b isoform-specific monoclonal antibody, in patients with FGFR2b+ gastric cancer. J Clin Oncol. 2017;35(15_suppl):4067.
   Google Scholar
• Presta M, Chiodelli P, Giacomini A, et al. Fibroblast growth factors (FGFs) in cancer: FGF traps as a new therapeutic approach. Pharmacol Ther. 2017;179:171–187.
   PubMed Web of Science ®Google Scholar
• Tao J, Xiang J-J, Li D, et al. Selection and characterization of a human neutralizing antibody to human fibroblast growth factor-2. Biochem Biophys Res Commun. 2010;394:767–773.
   PubMed Web of Science ®Google Scholar
• Wang L, Park H, Chhim S, et al. A novel monoclonal antibody to fibroblast growth factor 2 effectively inhibits growth of hepatocellular carcinoma xenografts. Mol Cancer Ther. 2012;11:864–872.
   PubMed Web of Science ®Google Scholar
• de Aguiar RB, Parise CB, Souza CR, et al. Blocking FGF2 with a new specific monoclonal antibody impairs angiogenesis and experimental metastatic melanoma, suggesting a potential role in adjuvant settings. Cancer Lett. 2016;371:151–160.
   PubMed Web of Science ®Google Scholar
• Tanaka A, Furuya A, Yamasaki M, et al. High frequency of fibroblast growth factor (FGF) 8 expression in clinical prostate cancers and breast tissues, immunohistochemically demonstrated by a newly established neutralizing monoclonal antibody against FGF 8. Cancer Res. 1998;58:2053–2056.
   PubMed Web of Science ®Google Scholar
• Shimada N, Ishii T, Imada T, et al. A neutralizing anti-fibroblast growth factor 8 monoclonal antibody shows potent antitumor activity against androgen-dependent mouse mammary tumors in vivo. Clin Cancer Res. 2005;11:3897–3904.
   PubMed Web of Science ®Google Scholar
• Maruyama-Takahashi K, Shimada N, Imada T, et al. A neutralizing anti-fibroblast growth factor (FGF) 8 monoclonal antibody shows anti-tumor activity against FGF8b-expressing LNCaP xenografts in androgen-dependent and -independent conditions. Prostate. 2008;68:640–650.
   PubMed Web of Science ®Google Scholar
• Harding TC, Long L, Palencia S, et al. Blockade of nonhormonal fibroblast growth factors by FP-1039 inhibits growth of multiple types of cancer. Sci Transl Med. 2013;5:178ra139.
   Web of Science ®Google Scholar
• Blackwell C, Sherk C, Fricko M, et al. Inhibition of FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP-1039/GSK3052230. Oncotarget. 2016;7:39861–39871.
   PubMed Web of Science ®Google Scholar
• Tolcher AW, Papadopoulos KP, Patnaik A, et al. A phase I, first in human study of FP-1039 (GSK3052230), a novel FGF ligand trap, in patients with advanced solid tumors. Ann Oncol. 2016;27:526–532.
   PubMed Web of Science ®Google Scholar
• Li D, Wei X, Xie K, et al. A novel decoy receptor fusion protein for FGF-2 potently inhibits tumour growth. Br J Cancer. 2014;111:68–77.
   PubMed Web of Science ®Google Scholar
• Giorgio C, Incerti M, Corrado M, et al. Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction. Biochem Pharmacol. 2018;147:21–29.
   PubMed Web of Science ®Google Scholar
• Foglieni C, Pagano K, Lessi M, et al. Integrating computational and chemical biology tools in the discovery of antiangiogenic small molecule ligands of FGF2 derived from endogenous inhibitors. Sci Rep. 2016;6:23432.
   PubMed Web of Science ®Google Scholar
• Leali D, Bianchi R, Bugatti A, et al. Fibroblast growth factor 2-antagonist activity of a long-pentraxin 3-derived anti-angiogenic pentapeptide. J Cell Mol Med. 2010;14:2109–2121.
   PubMed Web of Science ®Google Scholar
• Ronca R, Giacomini A, Di Salle E, et al. Long-pentraxin 3 derivative as a small-molecule FGF trap for cancer therapy. Cancer Cell. 2015;28:225–239.
   PubMed Web of Science ®Google Scholar
• Castelli R, Giacomini A, Anselmi M, et al. Synthesis, structural elucidation, and biological evaluation of NSC12, an orally available Fibroblast Growth Factor (FGF) ligand trap for the treatment of FGF-dependent lung tumors. J Med Chem. 2016;59:4651–4663.
   PubMed Web of Science ®Google Scholar
• Chiodelli P, Bugatti A, Urbinati C, et al. Heparin/Heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use. Molecules. 2015;20:6342–6363.
   PubMed Web of Science ®Google Scholar
• Castelli R, Porro F, Tarsia P. The heparins and cancer: review of clinical trials and biological properties. Vasc Med. 2004;9:205–213.
   PubMed Web of Science ®Google Scholar
• Daigo K, Inforzato A, Barajon I, et al. Pentraxins in the activation and regulation of innate immunity. Immunol Rev. 2016;274:202–217.
   PubMed Web of Science ®Google Scholar
• Giacomini A, Ghedini GC, Presta M, et al. Long pentraxin 3: a novel multifaceted player in cancer. Biochim Biophys Acta. 2017;1869:53–63.
   PubMed Web of Science ®Google Scholar
• Ronca R, Alessi P, Coltrini D, et al. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer. J Pathol. 2013;230:228–238.
   PubMed Web of Science ®Google Scholar
• Camozzi M, Rusnati M, Bugatti A, et al. Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3. J Biol Chem. 2006;281:22605–22613.
   PubMed Web of Science ®Google Scholar
• Bono F, De Smet F, Herbert C, et al. Inhibition of tumor angiogenesis and growth by a small-molecule multi-FGF receptor blocker with allosteric properties. Cancer Cell. 2013;23:477–488.
   PubMed Web of Science ®Google Scholar
• Herbert C, Schieborr U, Saxena K, et al. Molecular mechanism of SSR128129E, an extracellularly acting, small-molecule, allosteric inhibitor of FGF receptor signaling. Cancer Cell. 2013;23:489–501.
   PubMed Web of Science ®Google Scholar
• Ader I, Delmas C, Skuli N, et al. Preclinical evidence that SSR128129E – a novel small-molecule multi-fibroblast growth factor receptor blocker–radiosensitises human glioblastoma. Eur J Cancer. 2014;50:2351–2359.
   PubMed Web of Science ®Google Scholar
• Conn PJ, Christopoulos A, Lindsley CW. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov. 2009;8:41–54.
   PubMed Web of Science ®Google Scholar
• Christopoulos A. Allosteric binding sites on cell-surface receptors: novel targets for drug discovery. Nat Rev Drug Discov. 2002;1:198–210.
   PubMed Web of Science ®Google Scholar